Genitourinary Cancers Symposium 2013

Concurrent administration of sipuleucel-T and abiraterone acetate plus prednisone is comparable to sipuleucel-T alone in men with metastatic castration-resistant prostate cancer, according to research from the 2013 Genitourinary Cancers Symposium.

Serum androgens appear to be prognostic of overall survival among men with castration-resistant prostate cancer, according to research presented at the 2013 Genitourinary Cancers Symposium.

Radium-223 dichloride is associated with significant improvements in overall survival among patients with castration-resistant prostate cancer and bone metastases, according to research presented at the 2013 Genitourinary Cancers Symposium.

Use of corticosteroids during treatment with enzalutamide reduces survival and increases adverse events in men with mCRPC who previously underwent docetaxel therapy, according to research presented at the 2013 Genitourinary Cancers Symposium.

ARN-509 is safe and well tolerated in men with high-risk nonmetastatic castration-resistant prostate cancer, according to research presented at the 2013 Genitourinary Cancers Symposium.